Genetic Information

Gene & Transcript Details

Gene
PIK3CA
Transcript
NM_006218.4 MANE Select
Total Exons
Reference Sequence
NC_000003.11
Alternative Transcripts
IDStatusDetails
NM_006218.2 Alternative 3724 nt | 158–3364
NM_006218.3 Alternative 9104 nt | 158–3364
NM_006218.4 MANE Select 9259 nt | 324–3530

Variant Details

HGVS Notation
NM_006218.4:c.10_57del
Protein Change
R4_R19del
Location
Exon 2 (Exon 2 of )
2
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Unknown
0 publications
Clinical Statement

""

COSMIC Somatic Evidence

Open
COSMIC ID
Recurrence
0 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene PIK3CA.

Functional Studies & Therapeutic Relevance

Functional Summary

The variant PIK3CA R4_R19del has not been functionally characterized.

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Unknown
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.0 15 bp
- Donor Loss (DL) 0.05 14 bp
+ Acceptor Gain (AG) 0.02 208 bp
+ Donor Gain (DG) 0.15 202 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PVS1

PVS1 (Not Applied)

According to standard ACMG guidelines, the rule for PVS1 is: "Null Variant (nonsense, fs, start codon, splicing +1/2, startgain, single or multi-exon deletion) in a gene where LOF is a known mechanism of disease." The evidence for this variant shows an in‐frame deletion of amino acids R4_R19, which does not introduce a premature stop codon or disrupt canonical splice sites. Therefore, this criterion is not applied.

PS1

PS1 (Not Applied)

According to VCEP guidelines, the rule for PS1 is: "Same amino acid change as a previously established pathogenic variant regardless of nucleotide change." The evidence for this variant shows a multi‐amino acid deletion, not the same single amino acid substitution as any known pathogenic PIK3CA variant. Therefore, this criterion is not applied.

PS2

PS2 (Not Applied)

According to VCEP guidelines, the rule for PS2_Strong is: "The variant is present at a detectable allele fraction but is absent from parental samples with confirmed maternity and paternity, and present in affected tissue sample absent or lower in another tissue"; for PS2_Moderate: "Award if only one of those criteria is fulfilled." There are no parental or tissue‐fraction data for this variant. Therefore, this criterion is not applied.

PS3

PS3 (Not Applied)

According to VCEP guidelines, the rule for PS3 is: "Follow recommendations set forth by the SVI... (functional assay quality metrics required)." No functional studies have been performed for this variant. Therefore, this criterion is not applied.

PS4

PS4 (Not Applied)

According to VCEP guidelines, the rule for PS4_VeryStrong/Strong/Moderate/Supporting is: "Points are assigned for phenotype according to Table 2A; criterion applies only if variant is absent from controls (PM2)." There are no case‐level or segregation reports in the literature. Therefore, this criterion is not applied.

PM1

PM1 (Not Applied)

According to VCEP guidelines, the rule for PM1_Supporting is: "Residues affecting critical functional domains provided in Table 4 for each gene." The deleted region R4_R19 is not annotated as a critical functional domain in PIK3CA by the VCEP. Therefore, this criterion is not applied.

PM2

PM2 (Supporting)

According to VCEP guidelines, the rule for PM2_Supporting is: "Absent/rare from controls in an ethnically-matched cohort population sample ( ≥1)." The evidence for this variant shows it is absent from gnomAD and other population databases (MAF = 0%). Therefore, this criterion is applied at Supporting strength.

PM3

PM3 (Not Applied)

According to standard ACMG guidelines, the rule for PM3 is: "Detected in trans with a pathogenic variant for a recessive disorder." PIK3CA disorders are not recessive, and no trans data exist. Therefore, this criterion is not applied.

PM4

PM4 (Moderate)

According to standard ACMG guidelines, the rule for PM4 is: "Protein length changes due to in-frame deletions/insertions in a non-repeat region." The evidence shows an in-frame deletion of 16 amino acids (R4_R19del) in a non-repeat region of PIK3CA. Therefore, this criterion is applied at Moderate strength.

PM5

PM5 (Not Applied)

According to standard ACMG guidelines, the rule for PM5 is: "Moderate strength for a novel missense change at a residue where a different pathogenic missense change has been seen before." This variant is an in-frame deletion, not a missense substitution. Therefore, this criterion is not applied.

PM6

PM6 (Not Applied)

According to standard ACMG guidelines, the rule for PM6 is: "Assumed de novo without confirmation of paternity/maternity." No de novo information is available. Therefore, this criterion is not applied.

PP1

PP1 (Not Applied)

According to standard ACMG guidelines, the rule for PP1 is: "Co-segregation with disease in multiple affected family members." No segregation data are available. Therefore, this criterion is not applied.

PP2

PP2 (Not Applied)

According to VCEP guidelines, the rule for PP2_Supporting is: "Missense constraint z-score >3.09 in ExAC for PIK3CA." This variant is an in-frame deletion, not a missense change. Therefore, this criterion is not applied.

PP3

PP3 (Not Applied)

According to standard ACMG guidelines, the rule for PP3 is: "Multiple lines of computational evidence support a deleterious effect." Computational tools are not designed for multi-amino-acid in-frame deletions here, and SpliceAI predicts no splicing impact. There is insufficient evidence of deleterious effect. Therefore, this criterion is not applied.

PP4

PP4 (Not Applied)

According to standard ACMG guidelines, the rule for PP4 is: "Patient phenotype highly specific for a disease with a single genetic etiology." No phenotype or clinical correlation data are provided. Therefore, this criterion is not applied.

PP5

PP5 (Not Applied)

According to standard ACMG guidelines, the rule for PP5 is: "Reputable source reports variant as pathogenic." This variant is not found in ClinVar or other variant databases. Therefore, this criterion is not applied.

BA1

BA1 (Not Applied)

According to VCEP guidelines, the rule for BA1 is: "Allele frequency >0.0926% is stand-alone benign." The variant is absent from population databases. Therefore, this criterion is not applied.

BS1

BS1 (Not Applied)

According to VCEP guidelines, the rule for BS1 is: "Allele frequency >0.0185% is strong benign." The variant is absent from gnomAD (MAF = 0%). Therefore, this criterion is not applied.

BS2

BS2 (Not Applied)

According to VCEP guidelines, the rule for BS2_Strong is: "Observed in ≥3 healthy adults or homozygotes in gnomAD." No such observations exist. Therefore, this criterion is not applied.

BS3

BS3 (Not Applied)

According to VCEP guidelines, the rule for BS3 is: "Well-established functional studies show no damaging effect." No benign functional data exist. Therefore, this criterion is not applied.

BS4

BS4 (Not Applied)

According to standard ACMG guidelines, the rule for BS4 is: "Lack of segregation in affected family members." No segregation data are available. Therefore, this criterion is not applied.

BP1

BP1 (Not Applied)

According to standard ACMG guidelines, the rule for BP1 is: "Missense variant in gene where only LOF causes disease." Not applicable to an in-frame deletion in PIK3CA. Therefore, this criterion is not applied.

BP2

BP2 (Not Applied)

According to standard ACMG guidelines, the rule for BP2 is: "Observed in cis or trans with a pathogenic variant." No such data exist. Therefore, this criterion is not applied.

BP3

BP3 (Not Applied)

According to standard ACMG guidelines, the rule for BP3 is: "In-frame indels in a repetitive region." R4_R19 is not a repetitive sequence. Therefore, this criterion is not applied.

BP4

BP4 (Not Applied)

According to VCEP guidelines, the rule for BP4_Supporting is: "Applicable only to synonymous, intronic (non-canonical) or UTR variants if ≥2/3 splicing tools predict no impact." This is an in-frame deletion, not eligible. Therefore, this criterion is not applied.

BP5

BP5 (Not Applied)

According to standard ACMG guidelines, the rule for BP5 is: "Variant found in a case with an alternate molecular cause." No such reports exist. Therefore, this criterion is not applied.

BP6

BP6 (Not Applied)

According to standard ACMG guidelines, the rule for BP6 is: "Reputable source reports as benign." Not reported in any database. Therefore, this criterion is not applied.

BP7

BP7 (Not Applied)

According to standard ACMG guidelines, the rule for BP7 is: "Synonymous or intronic variant with no splicing impact and low conservation." Not applicable to an in-frame deletion. Therefore, this criterion is not applied.